Latest Research Collaboration News

INOVIQ Limited reported a $6.9 million net loss for FY25 while making significant strides in its exosome-based cancer diagnostics and therapeutics pipeline, including a breakthrough ovarian cancer screening test and promising CAR-exosome therapy results.

Cobram Estate Olives Limited has reported record financial results for FY2025, driven by strong sales growth in Australia and a doubling of branded sales in the USA. The company is shifting its capital expenditure focus to expand its Californian operations while maintaining sustainable growth in Australia.

Arovella Therapeutics reported a 14% reduction in net loss to $7.5 million for FY25, bolstered by a $15 million capital raise to fund its lead iNKT cell therapy program progressing toward a pivotal phase 1 clinical trial.

Invex Therapeutics reports a significantly reduced net loss for FY25, driven by lower R&D costs after closing its Phase III trial, while advancing promising pre-clinical Alzheimer’s research through a collaboration with Tessara Therapeutics.

Rhythm Biosciences has responded to an ASX price query following a sudden surge in its share price and trading volume, confirming no undisclosed information is driving the activity.

Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.

Electro Optic Systems (EOS) has secured its largest-ever order for the Slinger Counter-Drone system, boosting its contract backlog by 25% to $170 million and reporting strong cash flow and a debt-free balance sheet.

Latitude 66 has agreed to sell its 17.5% interest in the Greater Duchess Joint Venture for an upfront A$2 million, with potential for further contingent payments, while progressing exploration in Australia and Finland amid regulatory challenges.

Hawsons Iron Limited has validated a 100% dry processing circuit for its Hawsons Iron Project, securing $1.9 million in fresh capital and launching a key research collaboration with CSIRO to optimise pellet production.

Li-S Energy has secured a strategic defence collaboration, advanced its Pegasus I drone testing, and commissioned Australia's first lithium metal foil production line, all while maintaining a solid cash position.

Morella Corporation has secured key heritage approvals and government co-funding, while prioritising rubidium extraction research ahead of drilling at its Mt Edon and Mallina projects.

Invex Therapeutics has broadened its collaboration with Tessara Therapeutics to explore Exenatide’s potential in Alzheimer’s disease, while successfully renewing key orphan drug designations in Europe and the US.